Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.

3 Patients randomized to lixisenatide also had significantly greater reductions in the secondary endpoints for 2‐hour PPG ( P < 0.0001), average seven‐point SMPG ( P = 0.0290), and body weight ( P = 0.0108), with a trend toward significance for AUC SMPG at Week 24 compared with placebo (Figure 1 ).

also in 3,729 other papers

Although more lixisenatide‐treated patients than placebo‐treated patients achieved the composite endpoint of HbA1c <7.0% without documented symptomatic hypoglycemia (17.0% vs 7.3%; P = 0.1244) and HbA1c <7.0% without body weight gain or symptomatic hypoglycemia (8.3% vs 0%; P = 0.0682), the differences did not reach statistical significance in these subgroups.

also in 111,027 other papers

Similarly, in both renal groups at Week 24, patients treated with lixisenatide showed a trend for greater reductions in 2‐hour PPG, average seven‐point SMPG, AUC of SMPG, daily dose of basal insulin, and body weight compared with placebo; however, the difference was only significant for 2‐hour PPG ( P = 0.0004) and body weight ( P = 0.0126) in patients without moderate renal insufficiency (Table 3 ).

also in 53,322 other papers